Myovant Sciences Announces FDA Approval of ORGOVYX? (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
- ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO study
- Conference call and webcast to be held on December 21 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time